RT Journal
A1 MacLennan AH, Baber R
T1 HOrmone therapy use and risk of ovarian cancer
JF JAMA
JO JAMA
YR 2009
FD November 25
VO 302
IS 20
SP 2203
OP 2204
DO 10.1001/jama.2009.1724
UL http://dx.doi.org/10.1001/jama.2009.1724
AB 
The most common presentation of asymptomatic ovarian cancer is the chance finding of a pelvic mass at manual or ultrasonic pelvic examination.2 Women using HT are likely to present for routine pelvic examination more often than nonusers of HT. The potential for such detection bias was not discussed in the article but could account for the small annual increase in ovarian cancer incidence of 1 in 8300.